Trial Profile
A MULTICENTER, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms CCD
- 06 Sep 2023 Status changed from active, no longer recruiting to completed.
- 02 Feb 2021 Planned End Date changed from 1 Oct 2019 to 1 Oct 2022.
- 08 Dec 2020 Results of a pooled analysis (of data pooled from IST-CAR-506, IST-CAR-561 EMN01, RV-MM-PI-0752 and RV-MM-EMN-441 studies)assessing the incidence of severe infections, presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology